Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • Telephone

      • +972-77-2005042 from 8 AM - 11 PM IL

      • Contact
      • Contact

        +972-77-2005042
        from 8 AM - 11 PM IL

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Request More Information
      • Journalists
      • GDPR

      PixCell Medical's HemoScreen CBC Analyzer Achieves IVDR Certification--A Game-Changer for Point-of-Care Diagnostics

      PixCell Medical Logo

      News provided by

      PixCell Medical

      27 Nov, 2024, 12:00 IST

      Share this article

      Share this article


      YOKNEAM ILIT, Israel, Nov. 27, 2024 /PRNewswire/ -- PixCell Medical, a leading innovator in point-of-care diagnostics, proudly announces that its groundbreaking HemoScreen CBC analyzer has achieved certification under the In Vitro Diagnostic Medical Devices Regulation (IVDR) (EU) 2017/746. As the only FDA-cleared, point-of-care 5-part differential Complete Blood Count (CBC) analyzer, HemoScreen is now also the first device of its kind to meet the stringent IVDR requirements. This dual milestone cements PixCell Medical's position as a pioneer in advancing patient care through rapid, accurate, and portable diagnostic solutions.

      By securing IVDR certification years ahead of the regulatory deadline, HemoScreen reaffirms PixCell Medical's proactive commitment to quality, safety, and innovation. The rigorous certification process validated the analyzer's clinical performance, safety, and reliability across diverse healthcare settings, underscoring its role as a lab-accurate diagnostic tool at the point of care.

      Dr. Avishay Bransky, CEO of PixCell Medical, remarked: "Achieving IVDR certification for HemoScreen is more than a regulatory milestone—it's a validation of our mission to transform diagnostics at the point of care. By meeting the strictest regulatory standards in both the EU and the US, we're ensuring that healthcare providers worldwide have access to reliable, innovative tools that enhance patient care."

      PixCell Medical's IVDR certification process was conducted by Dekra, its EU Notified Body, and involved thorough evaluations of clinical evidence, performance data, and post-market surveillance standards. The certification confirms HemoScreen's compliance with the highest industry benchmarks for safety and efficacy.

      About PixCell Medical
      PixCell Medical, an innovator of rapid hematology testing solutions at the point-of-care, has developed the only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared for point-of-care use – the HemoScreen™.

      HemoScreen enables healthcare providers to perform rapid, high-quality CBC testing with just a single drop of blood and minimal training. Its patented disposable cartridges, preloaded with reagents, combined with AI-powered machine vision and Viscoelastic Focusing technology, make it uniquely suited for decentralized medical environments such as clinics, emergency rooms, and remote locations.

      For more information: www.pixcell-medical.com
      Follow PixCell Medical on LinkedIn and Twitter.

      Logo - https://mma.prnewswire.com/media/1501459/3647235/PixCell_Medical_Logo.jpg

      Media Contact:
      PixCell Medical
      Jake Jones
      [email protected]

      Modal title

      Also from this source

      PixCell Medical Expands into Canada Through Partnership with Inter Medico Following Health Canada Class III Licence for HemoScreen

      PixCell Medical Expands into Canada Through Partnership with Inter Medico Following Health Canada Class III Licence for HemoScreen

      PixCell Medical today announced its expansion into the Canadian market following the receipt of a Health Canada Class III Medical Device License for...

      HemoScreen Now Deployed Across More Than One-Third of NHS Mental Health Trusts, Supporting a New Integrated Diagnostics Model in Psychiatric Healthcare

      HemoScreen Now Deployed Across More Than One-Third of NHS Mental Health Trusts, Supporting a New Integrated Diagnostics Model in Psychiatric Healthcare

      More than one-third of NHS mental health trusts across the United Kingdom have now adopted PixCell Medical's HemoScreen point-of-care complete blood...

      More Releases From This Source

      Contact PR Newswire

      • +972-77-2005042
        from 8 AM - 11 PM IL

      Global Sites

      • APAC
      • APAC - Traditional Chinese
      • Asia
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany

       

      • India
      • Indonesia
      • Israel
      • Italy
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland

       

      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • United States

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921
      Global Sites
      • Asia
      • Brazil
      • Canada
      • Csezh
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Israel
      • Italie
      • Mexico
      • Middle East
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • United States
      +972-77-2005042
      from 8 AM - 11 PM IL
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • Cookie Settings
      Copyright © 2026 Cision US Inc.